Sign inJoin waitlistJoin the waitlist

Back to UPMC Medical Education Internal Medicine

Annie Im

Subspecialty Education Coordinator, Hematology / Oncology · UPMC Presbyterian

Credentials: ·

History

Hematology / Oncology · UPMC Presbyterian
Present

Research

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Blood · 2021 · 295 citations
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Review · Leukemia · 2014 · First of 7 authors · 219 citations
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Cytotherapy · 2017 · 152 citations

AR
Anastasios Raptis
21 papers
MA
Mounzer Agha
21 papers
JH
Jing-Zhou Hou
20 papers
Alison Sehgal
19 papers · 1 as a fellow
KD
Kathleen Dorritie
19 papers
MB
Michael Boyiadzis
19 papers
RF
Rafic Farah
18 papers
Steven Pavletic
18 papers
Robert Redner
14 papers
SL
Seah Lim
10 papers
Betty Hamilton
7 papers
Konstantinos Lontos
7 papers · 1 as a fellow

Clinical trials

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Principal investigator · Suspended · Phase 1
National Cancer Institute (NCI)
2024–2027
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Principal investigator · Withdrawn · Phase 2
University of Pittsburgh
2015–2016
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Principal investigator · Completed · Phase 2
Annie Im, M.D.
2013–2017
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027